⌘K
Loading ticker…
Nektar Therapeutics · Healthcare · Pharmaceutical Products
As of 2026-06-26, Nektar Therapeutics (NKTR) has a 3-month relative strength percentile of 25 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 58. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.1%, relative volume 6.42×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
25 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
NKTR is held by 4 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $62M notional. Top 3 carry $90M.
Top 4 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $62M |
| VXFVanguard Extended Market ETF | 0.03% | $23M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | 1.88% | $6M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NKTR Jan avg: -1.60% median: -7.53% win: 25% σ: 15.05% n: 4 2022-04-12 → 2026-05-29 | NKTR Feb avg: 16.99% median: 16.23% win: 75% σ: 56.03% n: 4 2022-04-12 → 2026-05-29 | NKTR Mar avg: -8.06% median: -7.37% win: 50% σ: 34.28% n: 4 2022-04-12 → 2026-05-29 | NKTR Apr avg: 14.45% median: 16.98% win: 80% σ: 29.50% n: 5 2022-04-12 → 2026-05-29 | NKTR May avg: -16.86% median: -15.74% win: 0% σ: 6.37% n: 5 2022-04-12 → 2026-05-29 | NKTR Jun avg: 35.94% median: 4.17% win: 50% σ: 68.08% n: 4 2022-04-12 → 2026-05-29 (current) | NKTR Jul avg: -2.67% median: -1.32% win: 50% σ: 10.96% n: 4 2022-04-12 → 2026-05-29 | NKTR Aug avg: 10.95% median: 5.27% win: 50% σ: 19.03% n: 4 2022-04-12 → 2026-05-29 | NKTR Sep avg: 18.36% median: 0.83% win: 75% σ: 49.02% n: 4 2022-04-12 → 2026-05-29 | NKTR Oct avg: 0.47% median: 2.83% win: 50% σ: 18.51% n: 4 2022-04-12 → 2026-05-29 | NKTR Nov avg: -6.21% median: -1.88% win: 50% σ: 13.36% n: 4 2022-04-12 → 2026-05-29 | NKTR Dec avg: -14.39% median: -18.85% win: 25% σ: 21.24% n: 4 2022-04-12 → 2026-05-29 |